Teva Pharmaceutical Industries Ltd ADR
TEVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$45.10 | Khd | Fypbmfnw |
Teva's North America Sales Dip Amid Delta's Effect on Physician Visits in Q3
Teva Pharmaceutical Industries' third-quarter results were generally in line with our forecasts. Revenue fell shy of our projections as the rise in delta variant cases suppressed broader pharmaceutical usage, so we expect sales to rebound somewhat next quarter. We maintain our $20 fair value estimate and no-moat rating.